nach oben

Erschienen in:

29.11.2022 | Original Article

Clinical outcomes and factors involved in the local control of proton beam therapy for oligometastatic liver tumors in patients with colorectal cancer

verfasst von: Hisashi Yamaguchi, M.D., Takahiro Kato, Ph.D., Michitaka Honda, Ph.D., Koichi Hamada, M.D., Yukitoshi Todate, M.D., Yojiro Ishikawa, Ph.D., Ichiro Seto, Ph.D., Takuya Tominaga, D.D.S, Masanori Machida, M.D., Yoshiaki Takagawa, M.D., Kanako Takayama, Ph.D., Motohisa Suzuki, M.D., Yasuhiro Kikuchi, Ph.D., Yasushi Teranishi, Ph.D., Masao Murakami, Ph.D., Shinichi Konno, Ph.D.

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

Background and purpose

There are no existing reports on proton beam therapy (PBT) for local control (LC) of liver metastasis of colorectal cancer (LMCRC). We calculated the LC rate of PBT for LMCRC and explored the influence of each factor on the LC rate.

Materials and methods

Cases in which PBT was performed at our center between 2009 and 2018 were retrospectively selected from the database. Patients with LMCRC without extrahepatic lesions and no more than three liver metastases were included. Effectiveness was assessed based on LC, overall survival (OS), and progression-free survival (PFS) rates. Adverse events (AEs) are described. Factors that may be related to LC were also investigated.

Results

This study included 23 men and 18 women, with a median age of 66 (range 24–87) years. A total of 63 lesions were included in the study. The most frequent dose was 72.6 Gy (relative biological effectiveness)/22 fractions. The median follow-up period was 27.6 months. The 3‑year LC, OS, and PFS rates were 54.9%, 61.6%, and 16.7%, respectively. Our multivariate analysis identified the distance between the tumor and the gastrointestinal (GI) tract as a factor associated with LC (P = 0.02). No grade ≥ 3 AEs were observed. None of the patients experienced liver failure during the acute or late phase.

Conclusion

Care must be taken with tumors that have reduced planning target volume coverage owing to organs at risk restrictions, especially in tumors near the GI tract.

Mizumoto M, Oshiro Y, Okumura T et al (2016) Proton beam therapy for Hepatocellular carcinoma: a review of the university of Tsukuba. Experience Int J Part Ther 2:570–578. https://doi.org/10.14338/IJPT-15-00035.2CrossRefPubMed

Fukumitsu N, Okumura T, Takizawa D et al (2015) Proton beam therapy for metastatic liver tumors. Radiother Oncol 117:322–327. https://doi.org/10.1016/J.RADONC.2015.09.011CrossRefPubMed

Coffman AR, Sufficool DC, Kang JI et al (2021) Proton stereotactic body radiation therapy for liver metastases-results of 5‑year experience for 81 hepatic lesions. J Gastrointest Oncol 12:1753–1760. https://doi.org/10.21037/JGO-20-424CrossRefPubMedPubMedCentral

Moyers MF, Miller DW, Bush DA, Slater JD (2001) Methodologies and tools for proton beam design for lung tumors. Int J Radiat Oncol Biol Phys 49:1429–1438. https://doi.org/10.1016/S0360-3016(00)01555-8CrossRefPubMed

Schwartz LH, Litière S, de Vries E et al (2016) RECIST 1.1-Update and clarification: from the RECIST committee. Eur J Cancer 62:132–137. https://doi.org/10.1016/J.EJCA.2016.03.081CrossRefPubMedPubMedCentral

Kanda Y (2013) Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant 48:452–458. https://doi.org/10.1038/BMT.2012.244CrossRefPubMed

Yamaguchi H, Honda M, Hamada K et al (2020) The effectiveness of proton beam therapy for liver metastatic recurrence in gastric cancer patients. Jpn J Clin Oncol 50:903–908. https://doi.org/10.1093/JJCO/HYAA052CrossRefPubMed

Fukumitsu N, Okumura T, Takizawa D et al (2017) Proton beam therapy for liver metastases from gastric cancer. J Radiat Res 58:357–362. https://doi.org/10.1093/JRR/RRW102CrossRefPubMed

Fukumitsu N, Okumura T, Numajiri H et al (2017) Follow-up study of liver metastasis from breast cancer treated by proton beam therapy. Mol Clin Oncol 7:56–60. https://doi.org/10.3892/MCO.2017.1283CrossRefPubMedPubMedCentral

10.

Shiba S, Shibuya K, Okamoto M et al (2021) Carbon-ion radiotherapy for oligometastatic colorectal cancer in the liver or lung. Anticancer Res 41:1997–2005. https://doi.org/10.21873/ANTICANRES.14967CrossRefPubMed

11.

Ahmed KA, Caudell JJ, El-Haddad G et al (2016) Radiosensitivity differences between liver metastases based on primary histology suggest implications for clinical outcomes after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 95:1399–1404. https://doi.org/10.1016/J.IJROBP.2016.03.050CrossRefPubMedPubMedCentral

12.

Chang DT, Swaminath A, Kozak M et al (2011) Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer 117:4060–4069. https://doi.org/10.1002/CNCR.25997CrossRefPubMed

13.

Doi H, Uemoto K, Suzuki O et al (2017) Effect of primary tumor location and tumor size on the response to radiotherapy for liver metastases from colorectal cancer. Oncol Lett 14:453–460. https://doi.org/10.3892/OL.2017.6167CrossRefPubMedPubMedCentral

14.

Goodman BD, Mannina EM, Althouse SK et al (2016) Long-term safety and efficacy of stereotactic body radiation therapy for hepatic oligometastases. Pract Radiat Oncol 6:86–95. https://doi.org/10.1016/J.PRRO.2015.10.011CrossRefPubMed

15.

Hoyer M, Roed H, Hansen AT et al (2006) Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol 45:823–830. https://doi.org/10.1080/02841860600904854CrossRefPubMed

16.

Three-fraction stereotactic body radiation therapy for isolated liver recurrence from colorectal cancer—PubMed. https://pubmed.ncbi.nlm.nih.gov/19856655/. Accessed 27 Mar 2022

17.

Liu E, Stenmark MH, Schipper MJ et al (2013) Stereotactic body radiation therapy for primary and metastatic liver tumors. Transl Oncol 6:442–446. https://doi.org/10.1593/TLO.12448CrossRefPubMedPubMedCentral

18.

McPartlin A, Swaminath A, Wang R et al (2017) Long-term outcomes of phase 1 and 2 studies of SBRT for hepatic colorectal metastases. Int J Radiat Oncol Biol Phys 99:388–395. https://doi.org/10.1016/J.IJROBP.2017.04.010CrossRefPubMed

19.

Méndez Romero A, Keskin-Cambay F, van Os RM et al (2017) Institutional experience in the treatment of colorectal liver metastases with stereotactic body radiation therapy. Rep Pract Oncol Radiother 22:126–131. https://doi.org/10.1016/J.RPOR.2016.10.003CrossRefPubMed

20.

Scorsetti M, Comito T, Tozzi A et al (2015) Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer. J Cancer Res Clin Oncol 141:543–553. https://doi.org/10.1007/S00432-014-1833-XCrossRefPubMed

21.

Stintzing S, Grothe A, Hendrich S et al (2013) Percutaneous radiofrequency ablation (RFA) or robotic radiosurgery (RRS) for salvage treatment of colorectal liver metastases. Acta Oncol 52:971–977. https://doi.org/10.3109/0284186X.2013.766362CrossRefPubMed

22.

van der Pool AEM, Méndez RA, Wunderink W et al (2010) Stereotactic body radiation therapy for colorectal liver metastases. Br J Surg 97:377–382. https://doi.org/10.1002/BJS.6895CrossRefPubMed

23.

Petrelli F, Comito T, Barni S et al (2018) Stereotactic body radiotherapy for colorectal cancer liver metastases: A systematic review. Radiother Oncol 129:427–434. https://doi.org/10.1016/J.RADONC.2018.06.035CrossRefPubMed

Titel: Clinical outcomes and factors involved in the local control of proton beam therapy for oligometastatic liver tumors in patients with colorectal cancer
verfasst von: Hisashi Yamaguchi, M.D.
Takahiro Kato, Ph.D.
Michitaka Honda, Ph.D.
Koichi Hamada, M.D.
Yukitoshi Todate, M.D.
Yojiro Ishikawa, Ph.D.
Ichiro Seto, Ph.D.
Takuya Tominaga, D.D.S
Masanori Machida, M.D.
Yoshiaki Takagawa, M.D.
Kanako Takayama, Ph.D.
Motohisa Suzuki, M.D.
Yasuhiro Kikuchi, Ph.D.
Yasushi Teranishi, Ph.D.
Masao Murakami, Ph.D.
Shinichi Konno, Ph.D.
Publikationsdatum: 29.11.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 3/2023
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-022-02023-z

Physical and nonphysical effects of weekly music therapy intervention on the condition of radiooncology patients

Original Article

Kardiovaskuläre Risikoevaluation in der Behandlung des Hodgkin-Lymphoms – auf dem Weg zur individualisierten Planung?

Open Access
Hodgkin-Lymphom
Kommentierte Studie

Palliative appropriateness criteria: external validation of a new method to evaluate the suitability of palliative radiotherapy fractionation

Open Access
Original Article

SBRT von primären Nierenzellkarzinomen – Langzeitergebnisse der IROCK-Datenbank

Open Access
Nierenkarzinom
Kommentierte Studie

Surgical resection versus transarterial chemoembolization followed by moderately hypofractionated radiotherapy in hepatocellular carcinoma

Original Article

The tumor core boost study: A feasibility study of radical dose escalation to the central part of large tumors with an integrated boost in the palliative treatment setting

Open Access
Original Article

Neu im Fachgebiet Onkologie

CDK4/6-Inhibitoren bei Brustkrebs in die Zweitlinie aufschieben?

10.01.2025
Mammakarzinom
Nachrichten

Ergebnisse einer Phase-III-Studie sprechen dafür, dass die Behandlung mit CDK4/6-Inhibitoren bei fortgeschrittenem HR-positivem, HER2-negativem Brustkrebs auch auf die Zweitlinie verschoben werden könnte, ohne die onkologischen Ergebnisse zu kompromittieren.

Cannabisextrakt verbessert Antiemese bei Chemotherapie

10.01.2025
Antiemetische Therapie
Nachrichten

Sprechen Krebskranke auf die übliche Antiemese während einer Chemotherapie nicht ausreichend an, lohnt sich möglicherweise eine Behandlung mit Cannabisextrakt. In einer Phase-2/3-Studie ließ sich die antiemetische Response mit einem solchen Extrakt erheblich verbessern.

Veränderung der Brustdichte beeinflusst das Krebsrisiko

08.01.2025
Mammakarzinom
Nachrichten

Die radiologische Dichte des Mammagewebes ist mit dem Risiko assoziiert, an Brustkrebs zu erkranken. Dabei wirken sich laut Ergebnissen einer Studie auch Dichteänderungen aus. Fünf Verlaufsmuster lassen sich dabei unterscheiden.

PMBCL mit CMR: Radiatio kann ohne Risiko weggelassen werden

08.01.2025
Non-Hodgkin-Lymphome
Nachrichten

Patienten mit primär mediastinalem B-Zell-Lymphom (PMBCL), die nach der Induktionstherapie eine komplette metabolische Remission (CMR) erreichen und keine konsolidierende Bestrahlung erhalten, müssen offenbar keine Überlebensnachteile fürchten.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Clinical outcomes and factors involved in the local control of proton beam therapy for oligometastatic liver tumors in patients with colorectal cancer